Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 1999The Prostate

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

View Full Paper
Ask AI
Bookmark
Share

Authors

SSS.J. SimmonsNorthwest Biotherapeutics (United States)BTB.A. TjoaCharles River Laboratories (United States)MRM. RogersNorthwest Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Simmons et al. (1999) studied this question.

synapsesocial.com/papers/6aa82cef86bd514de1ae5778https://doi.org/10.1002/(sici)1097-0045(19990601)39:4<291::aid-pros10>3.0.co;2-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.1996 · 735 citations
  2. 2Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen1996 · 394 citations
  3. 3The Dendritic Cell System and its Role in Immunogenicity1991 · 4,720 citations
  4. 4Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity1996 · 118 citations
  5. 5Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides1998 · 242 citations